David Mott
QuietNamed in filings at NEA
- Board seats filed
- 12
all filings on record
Named in filings at NEA
all filings on record
last 24 months
from a verified or cited source
| Tiburio Therapeutics | Biotech & pharma | December 2018 | None on file |
| Cydan II | Biotech & pharma | September 2017 | None on file |
| Complexa | Biotech & pharma | July 2017 | None on file |
| IMARA | Biotech & pharma | April 2016 | Orbimed Asia Partners, Orbimed Genesis |
| TESARO | Biotech & pharma | February 2016 | Westlake Biopartners |
| ARDELYX | Biotech & pharma | June 2015 | None on file |
| XTuit Pharmaceuticals | Biotech & pharma | November 2014 | Kendall Capital Partners |
| Prosensa Holding N.V. | Biotech & pharma | November 2014 | None on file |
| 3-V Biosciences | Biotech & pharma | October 2014 | Westlake Biopartners |
| Adaptimmune | Biotech & pharma | September 2014 | Orbimed Asia Partners, Orbimed Genesis |
| Mersana Therapeutics | Biotech & pharma | September 2013 | None on file |
| Omthera Pharmaceuticals | Biotech & pharma | February 2011 | None on file |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name David Mott on the board, based on 12 filed seats with a verified or cited source.